Accession Number: | 0001209191-22-043018 |
Date: | 2022-07-20 |
Issuer: | VERVE THERAPEUTICS, INC. (VERV) |
Original Submission Date: |
BELLINGER ANDREW
C/O VERVE THERAPEUTICS, INC.
500 TECHNOLOGY SQUARE, SUITE 901
CAMBRIDGE, MA 02139
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2022-07-20 | M | 20,000 | a | $1.39 | 26,629 | direct | ||
COMMON STOCK | 2022-07-20 | S | 20,000 | d | $34.90 | 6,629 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 1.39 | 2022-07-20 | deemed execution date | M | 20,000 (d) | 2029-06-24 | common stock 20,000 | $1.39 | 1,599 | direct |
ID | footnote |
---|---|
f1 | the sales reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on march 20, 2022. |
f2 | the option was granted on june 25, 2019 for 21,599 shares. the shares underlying the option vested on may 1, 2020. |